Granulocyte Macrophage Colony Stimulating Factor

This factor increases the production of white blood cells and is used to treat or prevent neutropenia in patient receiving myelosuppressive cancer chemotherapy. GM-CSF; such as Granulocyte , eosinophil production it acts synergistically with SCF.IL-1,IL-3,and IL-6 to stimulate CFU-GM and CFU-Meg to increase neutrophil and monocyte production. With EPO (Erythropoietin) may promote BFU-t formation. Prevents alveolar proteinosis. Sargramostim is an rhGM-CSF expressed by the yeast, saccharomyces cerevisiae. Molgramostim is an rhGM-CSF expressed by Escherichia coli. Molecular mass of rhGM-CSF prepared in E.coli, unglycosylated is 14kDA. The naturally occurring glycosylated compound has a molecular weight of up to 34kDa.

Granulocyte Macrophage Colony Stimulating Factor is primarily indicated in conditions like Acute myeloid leukemia, Bone marrow failure, Bone marrow transplantation, Chemotherapy induced neutropenia, Mobilization of peripheral blood progenitor cells, Neutropenia, and can also be given in adjunctive therapy as an alternative drug of choice in Aplastic anemia.

Granulocyte Macrophage Colony Stimulating Factor is contraindicated in conditions like Allergy, Leukemia, Cardiac disease.

The severe or irreversible adverse effects of Granulocyte Macrophage Colony Stimulating Factor, which give rise to further complications include Cardiac arrhythmias, Peripheral edema, Hemolytic anemia, Fluid retention, Weight gain, Pericarditis, Peritonitis, Acute myeloid leukemia, Capillary leak syndrome. Granulocyte Macrophage Colony Stimulating Factor produces potentially life-threatening effects which include elevation in Serum creatinine, Elevation of liver enzymes, Pericardial effusion, Anaphylactic reactions, Pleural effusion, Transient arrhythmias. which are responsible for the discontinuation of Granulocyte Macrophage Colony Stimulating Factor therapy. The symptomatic adverse reactions produced by Granulocyte Macrophage Colony Stimulating Factor are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Fever, Myalgia, Dyspnea, Rashes, GI upset, Malaise, Hypotension, Flushing, Bone pain, Arthralgia, Nausea and vomiting, Fluid retention, Transient hypotension, Allergic reaction.

It should not be used in patients with known hypersensitivity, yeast derived products or any component of the products, simultaneous use with chemo or radiotherapy. since GM-CSF such as Molgramostim can promote growth of myeloid cells in vitro their use in myeloid malignancies has been contra indicated, although recently colony stimulating factors have been used in some patients with myeloid diseases without stimulation of malignant cells. They should not be used from 24 hours before until 24 hours after malignant or malignant myeloid condition chemotherapy or cardiotherapy due to the sensitivity of rapidly dividing myeloid cells.

Drug should not be given to Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

4 to 32 ug/kg (18 (18)) 24 hourly IV Inf — As Required

1 to 10 ug/kg (5.5 (5.5)) 24 hourly IV Infusion — - 1 to 10 ug/kg (5.5 (5.5)) 24 hourly Intra Venous — - 1 to 10 ug/kg (5.5 (5.5)) 24 hourly Subcutaneous — -

No neonatal dosage information is recorded for this medicine yet.

No data regarding the interactions of Granulocyte Macrophage Colony Stimulating Factor was found.

Vial Store in a well closed container. Do not Freeze. Protect from Sunlight.